The MMRF Blog - Multiple Myeloma Research Foundation

The MMRF Blog

Post-transcriptional Modifications Contribute to the Upregulation of Cyclin D2 in Multiple Myeloma.

Misiewicz-Krzeminska I, Sarasquete ME, Vicente-Dueñas C, Krzeminski P, Wiktorska K, Corchete LA, Quwaider D, Rojas EA, Corral R, Martín AA, Escalante F, Bárez A, García JL, Sánchez-García I, García-Sanz R, San Miguel JF, Gutiérrez NC. Clin Cancer Res. 2016 Jan 1;22(1):207-17. doi: 10.1158/1078-0432.CCR-14-2796. Epub 2015 Sep 4. PMID: 26341922 [PubMed - in process] READ MORE

Posted: January 28, 2016

UCHL1 is a biomarker of aggressive multiple myeloma required for disease progression.

Hussain S, Bedekovics T, Chesi M, Bergsagel PL, Galardy PJ. Oncotarget. 2015 Dec 1;6(38):40704-18. doi: 10.18632/oncotarget.5727. PMID: 26513019 [PubMed - in process] Free Article READ MORE

Posted: January 28, 2016

Serum levels of soluble programmed death ligand 1 predict treatment response and progression free survival in multiple myeloma.

Wang L, Wang H, Chen H, Wang WD, Chen XQ, Geng QR, Xia ZJ, Lu Y. Oncotarget. 2015 Dec 1;6(38):41228-36. doi: 10.18632/oncotarget.5682. PMID: 26515600 [PubMed - in process] Free Article READ MORE

Posted: January 28, 2016

Page 30 of 81« First...1020...2829303132...405060...Last »